US-20260124262-A1 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS IN MAMMALIAN ANIMALS

US20260124262A1US 20260124262 A1US20260124262 A1US 20260124262A1US-20260124262-A1

Abstract

Pharmaceutical compositions, and methods of production and use for the treatment of neoplastic disease in a mammalian animal. When administered to an animal, the pharmaceutical compositions are useful for the treatment of neoplastic diseases such as various cancers, particularly those affecting mammalian animals such as companion animals.

Inventors

Alisha S. O'DELL

Assignees

GEROSYNTH LABORATORIES, INC.

Dates

Publication Date: 20260507
Application Date: 20251104

Claims (18)

1 . A method of treating a neoplastic disease in a mammalian subject, comprising administering to the subject an effective amount of a Medicinal Formulation, wherein the Medicinal Formulation is an emulsified Chaga mushroom solution containing chemical-modified compounds of the Chaga mushroom.
2 . The method of claim 1 , wherein the neoplastic disease is cancer.
3 . The method of claim 1 , wherein the cancer is melanoma, carcinoma, sarcoids, prostate cancer, colorectal cancer, breast cancer, liver cancer and brain cancer.
4 . The method of claim 1 , wherein the carcinoma is squamous cell carcinoma, basal cell carcinoma, or Merkel-cell carcinoma.
5 . A method of treating a dermatologic disease in a mammalian subject, comprising administering to the subject an effective amount of a Medicinal Formulation, wherein the Medicinal Formulation is an emulsified Chaga mushroom solution containing chemical-modified compounds of the Chaga mushroom.
6 . The method of claim 5 , wherein the dermatologic disease is atopic dermatitis, flea allergy dermatitis, contact dermatitis, bacterial infections, fungal infections or parasitic infestation.
7 . The method of claim 6 , wherein the dermatologic disease is a bacterial infection, and the bacterial infection is pyoderma.
8 . The method of claim 6 , wherein the dermatologic disease is a fungal infection, and the fungal infection is ringworm
9 . The method of claim 6 , wherein the dermatologic disease is a parasitic infestation and the parasitic infection is selected from the group consisting of mites and scabies.
10 . A method of treating a neurologic disease in a mammalian subject, comprising administering to the subject an effective amount of a Medicinal Formulation, wherein the Medicinal Formulation is an emulsified Chaga mushroom solution containing chemical-modified compounds of the Chaga mushroom.
11 . The method of claim 10 , wherein the neurologic disease is epilepsy, stroke, a brain tumor, a vestibular disease, degenerative myelopathy, an infectious disease, or a trauma.
12 . The method of claim 11 wherein the trauma is traumatic brain injury, trauma to the central nervous system, trauma to the peripheral nervous system, drug trauma, traumatic accidental injury, or blunt force trauma.
13 . The method of claims 1, 5 or 10 wherein the effective amount is a therapeutic dose of the Medicinal Formulation that treats the disease.
14 . The method of claim 13 , wherein the therapeutic dose is from 0.5 ml/10 lbs. of body weight to 3.0 ml/10 lbs. of body weight.
15 . The method of claims 1, 5 or 10 , wherein the administration is oral administration.
16 . The method of claim 15 , wherein the Medicinal Formulation is combined with a carrier to create a composition that facilitates oral administration.
17 . The method of claims 1, 5 or 10 , wherein the Medicinal Formulation contains a chemical compound having the formula of Formula 1, wherein R 1 , R 2 and R 3 are independently selected from the group consisting of alkyl/alkane, alkene/alkenyl, or alkyne/alkynyl, having from 1 to 20 carbon atom; benzene/aromatic/phenyl, ether, amide, alkyl halide, amine (-amino), alcohol/hydroxy/hydroxyl (—OH), thiol, aldehyde, ketone, ester, carboxylic acid (COOH), acid anhydride, acyl halide, or methyl, in a pharmaceutically-acceptable carrier; or wherein at least one of R 1 , R 2 and R 3 is a hydroxyl group; or wherein R 1 , R 2 and R 3 are hydroxyl groups
18 . The method of claims 1, 5 or 10 , wherein the Medicinal Formulation contains a chemical compound having the formula of Formula 2, wherein R 1 -R 7 are, independently, alkyl/alkane, alkene/alkenyl, or alkyne/alkynyl, having from 1 to 20 carbon atom; benzene/aromatic/phenyl, ether, amide, alkyl halide, amine (-amino), alcohol/hydroxy/hydroxyl (—OH), thiol, aldehyde, ketone, ester, carboxylic acid (COOH), acid anhydride, acyl halide, or methyl; or wherein R 1 -R 7 are, independently, alkyl/alkane, alkene/alkenyl, or alkyne/alkynyl, having from 1 to 20 carbon atom; benzene/aromatic/phenyl, ether, amide, alkyl halide, amine (-amino), alcohol/hydroxy/hydroxyl (—OH), thiol, aldehyde, ketone, ester, carboxylic acid (COOH), acid anhydride, acyl halide, or methyl, and wherein at least one of R 1 -R 7 is a hydroxyl group; or wherein R 1 -R 7 are hydroxyl groups.

Description

INCORPORATION BY REFERENCE Applicant's pending PCT/US24/27210, filed May 1, 2024 is incorporated by reference herein in its entirety. PRIORITY The present application claims the full benefit and priority of U.S. provisional applications 63/716,808 and 63/716,811, both filed Nov. 6, 2024. They are likewise fully incorporated by reference. FIELD The present invention relates generally to pharmaceutical compositions and methods for the treatment of a dermatologic, neurologic or neoplastic disease in mammalian animals. BACKGROUND OF THE INVENTION Here follows a preliminary discussion of the invention, which is not necessarily prior art, and should not necessarily be so construed. Dermatologic diseases in household pets are common. While all pets can have dermatologic diseases or disorders, they are most commonly observed in dogs. These diseases can arise from allergies, parasites, infections, or underlying internal issues. Examples include atopic dermatitis (environmental allergies), flea allergy dermatitis, contact dermatitis, bacterial and fungal infections, such as pyoderma and ringworm, and parasitic infestations such as mites and scabies. Symptoms frequently include itching, hair loss, skin redness, and secondary skin infections, requiring veterinary diagnosis, skin baths and ointment treatments, injections, administration of pharmaceuticals, and other treatment tailored to the specific cause. Atopic dermatitis is an inflammatory skin disease caused by a reaction to environmental allergens such as pollen, mold and dust mites. Flea allergy dermatitis is an allergic reaction to flea bites, causing intense itching (pruritus), skin irritation and possible hair loss (alopecia). Bacterial infections are often secondary to other conditions, the most common of which is pyoderma, an infection of hair follicles. Fungal infections, such as ringworm (dermatophytosis), a highly contagious skin infection, can spread from one animal to another, possibly including humans. Other fungal infections include systemic diseases such as blastomycosis, histoplasmosis and cryptococcosis. Parasitic infestations such as fleas, ticks, and mites, can cause itching and transmit diseases. Autoimmune diseases and disorders can also cause dermatologic problems as well. For example, pemphigus is an autoimmune disease in which the body's immune system attacks its own skin cells. In addition, hormonal disorders can cause skin issues, hair loss or changes in skin quality. Common neurologic diseases in pets can cause seizures, difficulty walking, and head tilting, and include conditions such as epilepsy, stroke, brain tumors, vestibular disease, degenerative myelopathy, and some infectious diseases. Symptoms vary by condition but may also include changes in behavior, loss of coordination, tremors, and paralysis. Diagnosis requires a veterinary exam and diagnostic tests, with treatments ranging from medication to surgery. Cancer is a disease that impacts pet owners around the world and is the leading cause of death in pets middle-aged and older. The increase in cancer diagnosis rates for dogs in the past 10 years has skyrocketed. According to the Veterinary Cancer Society, an average of one in four dogs will be diagnosed with cancer, with very limited treatment options that only promise to extend the life of the dog for a short time. The long-term prognosis for the survival of dogs with cancer is grim. And often the costs of treatment are prohibitive. Pet owners around the world are in desperate need of a real solution that delivers lasting results. There are no long-term treatment options for equines having advanced-stage cancer. Therefore, there is a critical need for novel, effective and less toxic therapeutic approaches to cancer, dermatologic and neurologic treatments for canine, feline, equine and other mammalian animals. Medicinal mushrooms and other natural products have been used to treat various diseases and infections for hundreds of years around the world. Today, medicinal mushrooms are used to treat many types of diseases including lung diseases and many types of cancer around the world. For more than 30 years, medicinal mushrooms have been approved as an addition to standard cancer treatments in Japan and China. In these countries, mushrooms have been used safely for a long time, either alone or combined with radiation or various chemotherapeutics. More than 100 different types of mushrooms are used to treat cancer in Asia, including Ganoderma lucidum (relish), Trametes versicolor or Curious versicolor (turkey tail), Lentinus edodes (shiitake), and Grifola frondosa (maitake). Since many mushrooms are edible and non-toxic, they provide the possibility that one or more of their constituent compounds may provide an effective, non-toxic treatment for cancer. Of particular interest is how mushrooms affect the immune system and if they stop or slow the growth of tumors or kill tumor cells. It is thought that certain chemical compounds, s